Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616180 | 0.83 | HTT (0.47) | HTTRECQLPKMALDH1A1KMT2A | |
| SCHEMBL14017807 | 0.83 | MAPT (0.39) | HTTRECQLPKMKMT2APOLB | |
| SCHEMBL14017786 | 0.81 | LMNA (0.41) | HTTALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL7855939 | 0.81 | CRHR1 (0.38) | KMT2AMEN1GAA | |
| SCHEMBL13718688 | 0.79 | GSK3B (0.40) | HTTALDH1A1MAPTTDP1GAA | |
| SCHEMBL27308984 | 0.79 | TRPV4 (0.38) | RECQLTDP1SMN1; SMN2 | |
| SCHEMBL18417808 | 0.79 | LMNA (0.36) | HTTRECQLALDH1A1MAPTALOX12 | |
| SCHEMBL741149 | 0.79 | KDM4E (0.46) | HTTALDH1A1POLBMAPTALOX12 | |
| SCHEMBL21600907 | 0.79 | IDO1 (0.43) | — | |
| SCHEMBL2841149 | 0.79 | KCNH3 (0.36) | HTTRECQLPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1259119-A | Substituted 3, 3-diamino-2-propenenitriles, their preparation and use | NOVO NORDISK AS (DK) | 2000-07-05 | — | — | CN | claimed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-RE48635-E1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-05-14 | — | — | US | disclosed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-8420689-B2 | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-04-16 | — | — | US | disclosed |
| WO-2012135799-A1 | SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-04 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| JP-2002145833-A | METHOD FOR PRODUCING 2,4-DIFLUORO-N-ISOPROPYLANILINE | HOKKO CHEM IND CO LTD | 2002-05-22 | — | — | JP | disclosed |
| US-5817876-A | ONE POT; REACTING AN NITROARENE WITH A CARBONYL COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | disclosed |
| EP-0491968-B1 | Process for the preparation of N-alkyl-fluoroanilines | BAYER AG (DE) | 1994-10-26 | — | — | EP | disclosed |
| EP-0491968-A1 | Process for the preparation of N-alkyl-fluoroanilines | BAYER AG (DE) | 1992-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | HTT 267/4885RECQL 3953/4885PKM 2199/4885 |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | HTT 141/4885RECQL 267/4885PKM 2065/4885 |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | HTT 3990/4885RECQL 174/4885PKM 4694/4885 |
| US-20160176896-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | HTT 4744/4885RECQL 4678/4885PKM 1686/4885 |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | HTT 4277/4885RECQL 1590/4885PKM 1616/4885 |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | HTT 2222/4885RECQL 1539/4885PKM 577/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | HTT 2959/4885RECQL 1405/4885PKM 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.